Form 4 for MBX MBX Biosciences, Inc.
Accepted 2024-09-17 00:00:00 ET · period of report 2024-09-16 · accession 0000950170-24-107525 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-09-17 | 2024-09-16 | MBX | Aynechi Tiba | Dir | P - Purchase | $16.00 | +750.0K | 2.14M | +54% | +$12.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | Aynechi Tiba | Dir | C - Cnv Deriv | — | +1.39M | 1.39M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Aynechi Tiba | Dir | C - Cnv Deriv | — | -16.67M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | P | A | 750,000 | $16.00 | 2,136,335 | I By Norwest Venture Partners XVI, LP | — | — | (F3) Reflects shares purchased in the Issuer's initial public offering. (F2) The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-09-16 | C | A | 1,386,335 | — | 1,386,335 | I By Norwest Venture Partners XVI, LP | — | — | (F1) Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. (F2) The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |
| 3 | Derivative | Series B Convertible Preferred Stock | 2024-09-16 | C | D | 16,666,666 | — | 0 | I By Norwest Venture Partners XVI, LP | — · — to — | 1,386,335 Common Stock | (F1) Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. (F2) The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |